Vaccine Case Studies

New Vaccine Landscape and Market Introduction Assessment

Situation

Many new life-saving vaccines will be available to developing countries between now and 2012. Global donors want to ensure they are available to the world?s poorest countries as quickly as possible. However, the introduction of these vaccines will be hindered by the lack of information to support vaccine adoption decision-making, limited country finances, competing country health care priorities, and global funding uncertainty.

Applied Strategies was comissioned by Global Alliance for Vaccines and Immunization (GAVI) and the World Bank to determine whether opportunities exist for the global community to improve the speed with which 72 of the poorest countries supported by GAVI are provided with the data they need to be ready to make vaccine adoption decisions and to assess the financial implications of introducing six new vaccines into their countries.

Contribution

• Worked across sectors of the global health community (BMGF, GAVI, WB, WHO, UNICEF) and vaccine teams ? human papillomavirus, Japanese encephalitis, malaria, meningococcal, pneumococcal, and rotavirus
• Developed and validated inputs leveraging key global community experts
• Derived 10 key decision-making criteria for new vaccine adoption
• Assessed the decision-making readiness of 72 GAVI-eligible countries across all six new vaccines
• Analyzed the financial implications of various future vaccine adoption scenarios
• Leveraged analysis results to develop new vaccine introduction frameworks and strategies for 2007?2010
• Supported recommendations with an innovative software solution

Results

• A current vaccine portfolio for each GAVI-eligible country
• The earliest date when key data will be available for an adoption decision on each vaccine by each country
• Cost to each country of its existing vaccine portfolio and potential new vaccines
• Cost to GAVI of existing and new vaccines given various financial scenarios
• Potential acceleration interventions for country?s readiness for adoption
• Insights into strategies that may be required to support the introduction of multiple new vaccines into GAVI-eligible countries

<< back